ABIOSEH PIEH: Open Payments
NPI 1982330312 · BEAR, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$898 in 28 payments from 10 companies in 2025. Trend: 2023 $19 · 2024 $1,092 · 2025 $898
Food & beverage: $818Education: $80
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 5 | $175 |
| Neurocrine BioSciences, Inc. | 4 | $172 |
| Alkermes, Inc. | 5 | $156 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $149 |
| Teva Pharmaceuticals USA, Inc. | 5 | $140 |
| Lilly USA, LLC | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| E.R. Squibb & Sons, L.L.C. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Indivior Inc. | 1 | $17 |
Products named: INGREZZA, FANAPT, CAPLYTA, LYBALVI, AUSTEDO XR, ARISTADA, MOUNJARO, Auvelity.
Industry payments across DE — which companies pay providers there.
